What are the FDA black‑box warnings, contraindications, and bone health considerations for the Depo‑Provera (medroxyprogesterone acetate) intramuscular injection?

FDA Black Box Warning and Key Safety Information for Depo-Provera

Depo-Provera (medroxyprogesterone acetate) carries an FDA black box warning for significant bone mineral density loss that may not be completely reversible, and should not be used for longer than 2 years unless other contraceptive options are inadequate. 1

Black Box Warning: Bone Mineral Density Loss

The FDA's most serious warning addresses three critical concerns 1:

• Progressive bone loss occurs with increasing duration of use and may not be completely reversible
• Unknown long-term fracture risk, particularly when used during adolescence or early adulthood (critical periods of bone accretion) — it remains unclear if this reduces peak bone mass and increases osteoporotic fracture risk later in life
• 2-year maximum recommendation unless other birth control methods are considered inadequate

Bone Health Considerations

BMD should be evaluated when a woman needs to continue Depo-Provera beyond 2 years. 1 The evidence shows:

• Adolescents treated for >2 years showed incomplete BMD recovery at the total hip and femoral neck even 5 years (60 months) after discontinuation 1
• Adults demonstrated only partial recovery of mean BMD at the total hip, femoral neck, and lumbar spine toward baseline by 2 years post-treatment 1
• Additional risk exists in patients with osteoporosis risk factors: metabolic bone disease, chronic alcohol/tobacco use, anorexia nervosa, strong family history of osteoporosis, or chronic use of anticonvulsants or corticosteroids 1

Absolute Contraindications

Depo-Provera is contraindicated in the following conditions 1:

1. Active thrombophlebitis or current/history of thromboembolic disorders or cerebrovascular disease
2. Known or suspected breast malignancy
3. Known hypersensitivity to medroxyprogesterone acetate or any ingredients
4. Significant liver disease
5. Undiagnosed vaginal bleeding

Dosing and Administration Requirements

The recommended dose is 150 mg IM every 13 weeks administered by deep intramuscular injection in the gluteal or deltoid muscle, rotating sites with each injection. 1

Critical timing requirements:

• First injection: ONLY during the first 5 days of normal menstrual period OR within first 5 days postpartum
• Exclusively breastfeeding mothers: Administer during or after the sixth postpartum week
• If interval >13 weeks: Determine patient is not pregnant before administering

Additional Safety Warnings

Thromboembolic Risk

Serious thrombotic events have been reported, though causality has not been established. Discontinue immediately if thrombosis develops, sudden vision loss, proptosis, diplopia, migraine, papilledema, or retinal vascular lesions occur. 1

Recent Meningioma Data

A 2025 US study found depot medroxyprogesterone acetate conferred a relative risk of 2.43 for meningioma diagnosis compared to controls, particularly with >4 years exposure or starting at age >31 years. However, the number needed to harm was 1,152 patients, suggesting low absolute clinical risk. 2

Clinical Pitfalls to Avoid

Based on physician survey data, common inappropriate practices following the black box warning include 3:

• Ordering routine BMD testing solely due to DMPA use (65% of surveyed physicians did this)
• Prescribing bisphosphonates based solely on DMPA use (inappropriate)
• Instituting arbitrary time limits without considering individual patient circumstances

The ACOG position (2014) clarifies that the bone effects of DMPA should not prevent prescribing or continuing use beyond 2 years — the decision must balance potential BMD effects against pregnancy risk and the known negative health consequences of unintended pregnancy, particularly in adolescents. 4